Plaintiffs Battle For Lead Role In Vytorin ERISA Suit

Law360, New York (July 1, 2008, 12:00 AM EDT) -- The lead plaintiffs in a shareholder lawsuit over Merck & Co. Inc.'s shelved Vioxx painkiller have asked to assume the role of lead plaintiff in a new proposed multidistrict litigation over allegations that the company covered up evidence that its cholesterol drug Vytorin was less effective than advertised.

In a motion filed last Monday in the U.S. District Court for the District of New Jersey, the plaintiffs asked that Schatz Nobel Izard PC and Schiffrin Barroway Topaz & Kessler LLP, who represent them in the Vioxx...
To view the full article, register now.